Clinical trial
A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid…
NCT00048568 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00048568 |
|---|---|
| Title | A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate |
| Official title | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy With Methotrexate Versus Methotrexate Alone in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | Abatacept, Methotrexate, Placebo |
| Enrollment | 1,250 |
| Start date | Dec 1, 2002 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Nov 13, 2002 |
| Last update posted | Dec 5, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: